Imaginab, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.imaginab.com
CD8 Minibody Repeatability Study
- Conditions
- MelanomaRenal Cell Carcinoma
- Interventions
- Biological: Zirconium 89Zr crefmirlimab berdoxam
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05744128
- Locations
- 🇬🇧
Castle Hill Hospital, Hull, United Kingdom
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
- Conditions
- Renal Cell CarcinomaMelanomaMerkel Cell Carcinoma, UnspecifiedNon Small Cell Lung Cancer
- Interventions
- Biological: zirconium Zr 89 crefmirlimab berdoxam
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05013099
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Macquarie University Hospital, Macquarie Park, New South Wales, Australia
🇺🇸CARTI Cancer Center, Little Rock, Arkansas, United States
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
- Conditions
- Metastatic Solid TumorsPositron-Emission Tomography
- Interventions
- Drug: ⁸⁹Zr-Df-IAB22M2C
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT03802123
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸Keck Hospital of USC, Los Angeles, California, United States
🇺🇸LAC + USC Medical Center, Los Angeles, California, United States
⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma
- Conditions
- Hodgkin LymphomaMetastatic Solid MalignanciesPositron-Emission TomographyImmunomodulation
- Interventions
- Drug: ⁸⁹Zr-Df-IAB22M2C Infusion
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03107663
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Honor Health and Imaging Endpoints, Scottsdale, Arizona, United States
A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Radiation: [89Zr]Df-IAB2M
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- ImaginAb, Inc.
- Registration Number
- NCT02424513
- Locations
- 🇺🇸
Washington University, St Louis, Missouri, United States
Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy
- Conditions
- Prostate Cancer
- Interventions
- Radiation: [89Zr]Df-IAB2M
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT02349022
- Locations
- 🇺🇸
Arizona Urology Specialists, Scottsdale, Arizona, United States
Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer
- Conditions
- Metastatic Prostate Cancer
- Interventions
- Biological: [89Zr]Df-IAB2M
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- ImaginAb, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01923727
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States